Novartis has accelerated its efforts to develop protein degrader therapies by licensing a prostate cancer candidate from Arvinas on the brink of starting phase 3 trials in a deal worth over $1 ...

Nepal is set to establish its first-ever cyclotron facility in Dhading within the next nine months. This will improve cancer detection and treatment in the country. The initiative, launched on World ...

1Tsukuba Research Laboratory, Eisai Co., Ltd., Ibaraki, Japan.

Protein degrader drugs harness the natural protein-denaturing machinery in cells to remove rogue proteins associated with disease, and have been proposed as a way to address a wide range of ...

Look closely at this image, stripped of its caption, and join the moderated conversation about what you and other students see. By The Learning Network Look closely at this image, stripped of ...

We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.

1Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland. 2Chemical Biology Laboratory, National Cancer Institute ...